Mr. James Passin reports

BIOVAXYS ENGAGES ENCLAVE CAPITAL LLC TO ACT AS AN AGENT IN BROKERED PRIVATE PLACEMENT OFFERING

Biovaxys Technology Corp. has engaged Enclave Capital LLC to act as an agent, in collaboration with D12 Capital Markets Inc. and its affiliate, Foundation Markets Inc., in connection with the company's previously announced brokered private placement LIFE financing.

Upon successful closing of the offering, Enclave will receive a cash fee equal to 8 per cent of the total proceeds received by the company from Enclave investors. In addition to the offering fee, the company will pay Enclave a cash fee of $10,000.

All other terms and conditions of the offering as previously announced on May 30, 2025, and amended on June 20, 2025, remain unchanged.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 -- Prospectus Exemptions, the units of the company issuable under the offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption (LIFE) under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the units under the offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws.

There is an amended offering document dated July 7, 2025, related to the offering that can be accessed under the company's profile at SEDAR+ and on the company's website. Prospective investors should read this offering document before making an investment decision.

About Biovaxys Technology Corp.

Biovaxys Technology, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix tumour cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy and other immunological diseases. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust and persistent immune response. The company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX platform, and in phase IIB clinical development for advanced relapsed-refractory diffuse large B cell lymphoma (DLBCL) and platinum-resistant ovarian cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. Biovaxys is also developing DPX+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX-RSV for respiratory syncytial virus, DPX+rPA for peanut allergy prophylaxis and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix "neoantigen" tumour cell construct platform for refractive late-stage ovarian cancer.

We seek Safe Harbor.